Abstract:Currently, the effect of AIDS single-target chemotherapy is severely compromised by the quick emergence of resistant HIV strains. Highly active antiretroviral therapy (HAART) combines HIV reverse transcriptase inhibitors with protease inhibitors or integrase inhibitors, and successfully suppresses HIV viral load to an undetectable level, dramatically improving the life quality of AIDS patients. However, the benefits of this approach are often compromised by poor patient compliance. Recently, there has been a move toward multicomponent drugs whereby two or more agents are coformulated in a single tablet to make dosing regimes simpler and thereby to improve patient compliance, but there are significant risks involved in the development of multicomponent drugs. Designed multiple ligands (DMLs) therapy as an emerging anti-HIV drug discovery paradigm, using a single entity to inhibit multitargets could yield improved patient compliance, thus reducing the likelihood of drug resistance. The exploration of such multifunctional ligands has proven valuable for anti-HIV leads discovery. However, presently many multifunctional scaffolds were first discovered by serendipity or screening; rational design by combining existing monofunctional scaffolds remains an enormous challenge. A key issue in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile. This review of literature examples introduce numerous attractive lead compounds, capable of interfering with different stages of HIV infection and AIDS pathogenesis, which reveals trends and insights that might provide valuable clues for novel anti-HIV drug design and help medicinal chemists discover the next generation of multiple ligands.

Rational Design of Multi-Target-Directed Ligands: Strategies and Emerging Paradigms.

Recent Advances in the Rational Drug Design Based on Multi-target Ligands.

Recent Advances In The Rational Drug Design Based On Multi-Target Ligands

Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist

Advancement of Multi-Target Drug Discoveries and Promising Applications in the Field of Alzheimer's Disease.

Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors

Design of Multi-Drug Combinations for Poly-Pharmacological Effects Using Composition-Activity Relationship Modeling and Multi-Objective Optimization Approach: Application in Traditional Chinese Medicine

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Rationally Designed Multitarget Anti-HIV Agents

Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands

What are the challenges with multi-targeted drug design for complex diseases?

Computational Multitarget Drug Design.

The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases

Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy.

Recent advances in multitarget-directed ligands via in silico drug discovery

Rationally designed multitarget anticancer agents.

Systematic Investigation of Dual-Target-Directed Ligands

Application Advances on Novel Techniques in Multi-target Drugs Discovery

Designed Multiple Ligands: an Emerging Anti-HIV Drug Discovery Paradigm

[Multi-Target Therapeutics and New Drug Discovery].

Polypharmacology In Drug Discovery: A Review From Systems Pharmacology Perspective